Results 91 to 100 of about 3,904 (178)

PO:05:069 | Risankizumab efficacy in peripheral and axial involvement: monocentric experience

Reumatismo
Risankizumab, an anti–IL-23 monoclonal antibody, is approved for the treatment of peripheral psoriatic arthritis (PsA), and increasing evidence suggests its potential efficacy in patients with concurrent axial involvement.
Società Italiana di Reumatologia
doaj  

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real‐world study [PDF]

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world ...
Ligrone, Luigi, Musumeci, ML, Amerio, Paolo, Uzzauto, Maria Teresa, Amerio, P, Uzzauto, MT, Guarneri, Claudio, Puca, RV, Lembo, Serena, Fargnoli, MC, Balato, A, Puca, Rosa Valentina, Musumeci, Maria Letizia, Balato, Anna, Guarneri, C, Raimondo, A, Cusano, Francesco, Cusano, F, Fargnoli, Maria Concetta, Megna, Matteo, Lembo, S, Raimondo, Annunziata, Megna, M, Ligrone, L   +23 more
core   +1 more source

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study

Dermatology and Therapy
Introduction Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and
Federico Diotallevi, Giulia Matacchione, Anna Campanati, Elena Marinelli Busilacchi, Nadia Viola, Ilaria Pace, Beatrice Fontana, Roberta Roncarati, Massimiliano Bonafè, Manuela Ferracin, Jacopo Sabbatinelli, Fabiola Olivieri   +11 more
doaj   +1 more source

Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16

Dermatology and Therapy
Introduction Psoriasis (PsO) in the genital and scalp areas is associated with increased patient burden and impact on quality of life. Effective treatments for PsO in these high-impact areas are essential, though patients are frequently excluded from ...
Eingun James Song, Benjamin Ehst, Brad Glick, George Michael Lewitt, Phoebe Rich, Navid Ezra, Jerry Bagel, Toni Anschutz, Brenton Bialik, Chenyang Duan, Doug Ashley, Manish Patel, Greg St. John, Arathi R. Setty, Lindsay Ackerman   +14 more
doaj   +1 more source

50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study [PDF]

Background: The phase-4, IMMpulse study (NCT04908475) has demonstrated superior efficacy and safety of risankizumab compared to apremilast in systemic-eligible adult patients with moderate plaque psoriasis (1). Methods: At baseline, 118 patients received
Pinter, Andreas, Stakias, Vassilis, Tyring, Stephen K, Stein-Gold, Linda, Papp, Kim A, Wu, Tianshuang, Pavlovsky, Lev, Hong, H. Chih-ho, Reich, Adam, Richter, Sven   +9 more
core  

Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report. [PDF]

CEN Case Rep
Yagasaki M, Yamada K, Koshida T, Takagi M, Saeki H, Ogiwara K, Kobayashi T, Kihara M, Gohda T, Suzuki Y.   +9 more
europepmc   +1 more source

Efficacy and safety of risankizumab in moderate to severe psoriasis: an updated systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Shuja H, Farhan K, Wamiq U, Khan MS, Tariq MB, Shakir S, Uzair M, Salomon I.   +7 more
europepmc   +1 more source

Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis. [PDF]

ACG Case Rep J
Srivoleti P, Dhillon N, Boneschansker L.
europepmc   +1 more source

Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study. [PDF]

Dermatol Ther (Heidelb)
Hsu CC, Huang YH, Tsai TF.
europepmc   +1 more source

The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study. [PDF]

An Bras Dermatol
Pehlivan Ulutaş G, Özkök Akbulut T, Polat Ekinci A.   +2 more
europepmc   +1 more source